|
GS185131: GO:0044699 single-organism process
|
|
GS192507: GO:0006812 cation transport
|
|
GS163321: MP:0010240 decreased skeletal muscle size
|
|
GS169127: MP:0002445 abnormal mononuclear cell differentiation
|
|
GS174310: HP:0100705 Abnormality of the glial cells
|
|
GS204629: GO:1901564 organonitrogen compound metabolic process
|
|
GS165814: MP:0001922 reduced male fertility
|
|
GS136552: proteinuria 5 (Ptnu5, Published QTL Chr 15)
|
|
GS171644: HP:0011842 Abnormality of skeletal morphology
|
|
GS201430: GO:0005516 calmodulin binding
|
|
GS178582: GO:0047499 calcium-independent phospholipase A2 activity
|
|
GS199036: GO:0016298 lipase activity
|
|
GS186720: GO:0032844 regulation of homeostatic process
|
|
GS125688: Arachidonic Acid interacting genes (MeSH:D016718) in CTD
|
|
GS136932: vertebral trabecular bone trait 17 (Vtbt17, Published QTL Chr 15)
|
|
GS175130: HP:0000750 Delayed speech and language development
|
|
GS188698: GO:0003012 muscle system process
|
|
GS169830: MP:0005384 cellular phenotype
|
|
GS174134: HP:0002012 Abnormality of the abdominal organs
|
|
GS169978: MP:0006035 abnormal mitochondrion morphology
|
|
GS189451: GO:0034765 regulation of ion transmembrane transport
|
|
GS164564: MP:0003871 abnormal myelin sheath morphology
|
|
GS202940: GO:0006935 chemotaxis
|
|
GS188494: GO:0042311 vasodilation
|
|
GS164727: MP:0001515 abnormal grip strength
|
|
GS190371: GO:0090066 regulation of anatomical structure size
|
|
GS176385: HP:0001249 Intellectual disability
|
|
GS135724: dissociation of activity 2 (Disso2, Published QTL Chr 15)
|
|
GS168334: MP:0002619 abnormal lymphocyte morphology
|
|
GS176107: HP:0000929 Abnormality of the skull
|
|
GS187887: GO:0080090 regulation of primary metabolic process
|
|
GS180879: GO:0051247 positive regulation of protein metabolic process
|
|
GS206874: GO:0006650 glycerophospholipid metabolic process
|
|
GS192691: GO:0015630 microtubule cytoskeleton
|
|
GS135475: brachyury modifier 2 (Brm2, Published QTL Chr 15)
|
|
GS166858: MP:0000685 abnormal immune system morphology
|
|
GS163965: MP:0011182 decreased hematopoietic cell number
|
|
GS171880: HP:0003134 Abnormality of peripheral nerve conduction
|
|
GS121755: 2,2',4,6-tetrachlorobiphenyl interacting genes (MeSH:C447028) in CTD
|
|
GS178334: GO:0007267 cell-cell signaling
|
|
GS136865: T cell receptor induced activation 2 (Tria2, Published QTL Chr 15)
|
|
GS169585: MP:0001413 abnormal response to new environment
|
|
GS184324: GO:0010646 regulation of cell communication
|
|
GS173061: HP:0003676 Progressive disorder
|
|
GS172054: HP:0001507 Growth abnormality
|
|
GS186215: GO:0048519 negative regulation of biological process
|
|
GS177404: GO:0005737 cytoplasm
|
|
GS189749: GO:0050796 regulation of insulin secretion
|
|
GS201251: GO:0044424 intracellular part
|
|
GS193238: GO:0031323 regulation of cellular metabolic process
|
|
GS163837: MP:0008026 abnormal brain white matter morphology
|
|
GS129102: bone mineral density 4 (Bmd4 Published QTL Chr 15)
|
|
GS170569: MP:0005404 abnormal axon morphology
|
|
GS178359: GO:0071840 cellular component organization or biogenesis
|
|
GS181893: GO:0048522 positive regulation of cellular process
|
|
GS135629: collagen induced arthritis 35 (Cia35, Published QTL Chr 15)
|
|
GS177440: GO:0006915 apoptotic process
|
|
GS192508: GO:0006811 ion transport
|
|
GS84289: cocaine related behavior (Published QTL, Chr 15)
|
|
GS182238: GO:0016298 lipase activity
|
|
GS183543: GO:0051179 localization
|
|
GS198639: GO:0046471 phosphatidylglycerol metabolic process
|
|
GS178357: GO:0071842 cellular component organization at cellular level
|
|
GS210666: GO:0044106 cellular amine metabolic process
|
|
GS188704: GO:0003018 vascular process in circulatory system
|
|
GS193414: GO:0044249 cellular biosynthetic process
|
|
GS189485: GO:0023051 regulation of signaling
|
|
GS185592: GO:0071331 cellular response to hexose stimulus
|
|
GS189561: GO:0001934 positive regulation of protein phosphorylation
|
|
GS169735: MP:0004543 abnormal sperm physiology
|
|
GS163824: MP:0001259 abnormal body weight
|
|
GS136321: non-HDL QTL 9 (Nhdlq9, Published QTL Chr 15)
|
|
GS191408: GO:0051924 regulation of calcium ion transport
|
|
GS176615: HP:0000277 Abnormality of the mandible
|
|
GS173242: HP:0001337 Tremor
|
|
GS180877: GO:0051241 negative regulation of multicellular organismal process
|
|
GS189325: GO:0048584 positive regulation of response to stimulus
|
|
GS177572: GO:0016042 lipid catabolic process
|
|
GS169512: MP:0002651 abnormal sciatic nerve morphology
|
|
GS186699: GO:0090036 regulation of protein kinase C signaling cascade
|
|
GS170933: HP:0001288 Gait disturbance
|
|
GS176203: HP:0000478 Abnormality of the eye
|
|
GS172185: HP:0002977 Aplasia/Hypoplasia involving the central nervous system
|
|
GS179901: GO:0071715 icosanoid transport
|
|
GS192671: GO:0055085 transmembrane transport
|
|
GS183513: GO:0019216 regulation of lipid metabolic process
|
|
GS196080: GO:0040011 locomotion
|
|
GS175552: HP:0002510 Spastic tetraplegia
|
|
GS176591: HP:0001276 Hypertonia
|
|
GS84288: METH responses for home cage activity (Published QTL, Chr 15)
|
|
GS135960: HDL QTL 27 (Hdlq27, Published QTL Chr 15)
|
|
GS189106: GO:0008015 blood circulation
|
|
GS173449: HP:0002683 Abnormality of the calvaria
|
|
GS165261: MP:0001393 ataxia
|
|
GS166409: MP:0002114 abnormal axial skeleton morphology
|
|
GS175171: HP:0001315 Reduced tendon reflexes
|
|
GS188792: GO:0070838 divalent metal ion transport
|
|
GS192299: GO:0006793 phosphorus metabolic process
|
|
GS175390: HP:0011007 Age of onset
|
|
GS176018: HP:0002317 Unsteady gait
|
|
GS178401: GO:0019637 organophosphate metabolic process
|
|
GS178913: GO:0042221 response to chemical stimulus
|
|
GS186744: GO:0043226 organelle
|
|
GS136113: liver Gapd decay rate 2 (Lgdr2, Published QTL Chr 15)
|
|
GS167070: MP:0001921 reduced fertility
|
|
GS169828: MP:0005386 behavior/neurological phenotype
|
|
GS181846: GO:0046471 phosphatidylglycerol metabolic process
|
|
GS182835: GO:0005622 intracellular
|
|
GS186655: GO:0035249 synaptic transmission, glutamatergic
|
|
GS189224: GO:0007610 behavior
|
|
GS202415: GO:0044710 single-organism metabolic process
|
|
GS213074: Genes with suggestive difference in (B6PF1) vs (PB6F1 + B6 + PWD) comparison
|
|
GS182703: GO:0051171 regulation of nitrogen compound metabolic process
|
|
GS136637: salmonella enteritidis susceptibility 3 (Ses3, Published QTL Chr 15)
|
|
GS181177: GO:0052689 carboxylic ester hydrolase activity
|
|
GS207903: GO:0044281 small molecule metabolic process
|
|
GS35939: Striatum Gene expression correlates of Handling induced convulsions 7 hrs after ethanol in Males BXD
|
|
GS179898: GO:0008610 lipid biosynthetic process
|
|
GS166244: MP:0002752 abnormal somatic nervous system morphology
|
|
GS188835: GO:0014832 urinary bladder smooth muscle contraction
|
|
GS33980: Striatum Gene expression correlates of Morphine distance (cm) travelled minutes 45-60 in Females & Males BXD
|
|
GS194133: GO:0005737 cytoplasm
|
|
GS14888: Differentially expressed genes modulated by nicotine in five combined brain regions (Amyg, HP, NA, PFC and VTA) for C3H/HeJ mice
|
|
GS167627: MP:0005460 abnormal leukopoiesis
|
|
GS187103: GO:0010821 regulation of mitochondrion organization
|
|
GS190737: GO:0071322 cellular response to carbohydrate stimulus
|
|
GS191375: GO:0005813 centrosome
|
|
GS180532: GO:0050880 regulation of blood vessel size
|
|
GS210231: GO:0004620 phospholipase activity
|
|
GS136513: prion incubation time 4 (Pitm4, Published QTL Chr 15)
|
|
GS170394: MP:0005112 abnormal spinal cord ventral horn morphology
|
|
GS171072: HP:0000572 Visual loss
|
|
GS136561: QTL for body weight independent of sex 4 (Qbis4, Published QTL Chr 15)
|
|
GS135269: alopecia areata 4 (Alaa4, Published QTL Chr 15)
|
|
GS174217: HP:0005105 Abnormal nasal morphology
|
|
GS180142: GO:0048878 chemical homeostasis
|
|
GS175525: HP:0000004 Onset and clinical course
|
|
GS191129: GO:0016787 hydrolase activity
|
|
GS136057: IgA nephropathy QTL 3 (Ignpq3, Published QTL Chr 15)
|
|
GS192347: GO:0010627 regulation of intracellular protein kinase cascade
|
|
GS192438: GO:0002791 regulation of peptide secretion
|
|
GS135630: collagen induced arthritis 37 (Cia37, Published QTL Chr 15)
|
|
GS115114: 10% Ethanol Preference
|
|
GS187747: GO:0019226 transmission of nerve impulse
|
|
GS169923: MP:0009458 abnormal skeletal muscle size
|
|
GS193234: GO:0031328 positive regulation of cellular biosynthetic process
|
|
GS174764: HP:0007367 Atrophy/Degeneration affecting the central nervous system
|
|
GS209634: GO:0015630 microtubule cytoskeleton
|
|
GS186301: GO:0031401 positive regulation of protein modification process
|
|
GS163803: MP:0003631 nervous system phenotype
|
|
GS169285: MP:0005092 decreased double-positive T cell number
|
|
GS172572: HP:0000347 Micrognathia
|
|
GS173079: HP:0000496 Abnormality of eye movement
|
|
GS181193: GO:0034976 response to endoplasmic reticulum stress
|
|
GS183767: GO:0019725 cellular homeostasis
|
|
GS165386: MP:0001262 decreased body weight
|
|
GS174994: HP:0002059 Cerebral atrophy
|
|
GS178700: GO:0060341 regulation of cellular localization
|
|
GS189751: GO:0050794 regulation of cellular process
|
|
GS180021: GO:0046903 secretion
|
|
GS135320: accelerator of polyoma-induced mammary tumors 1 (Apmt1, Published QTL Chr 15)
|
|
GS172857: HP:0004305 Involuntary movements
|
|
GS182325: GO:0051716 cellular response to stimulus
|
|
GS185959: GO:0051047 positive regulation of secretion
|
|
GS195668: GO:0042221 response to chemical stimulus
|
|
GS191617: GO:0017157 regulation of exocytosis
|
|
GS173991: HP:0000505 Visual impairment
|
|
GS209010: GO:1901575 organic substance catabolic process
|
|
GS126584: Tetrachlorodibenzodioxin interacting genes (MeSH:D013749) in CTD
|
|
GS168920: MP:0002674 abnormal sperm motility
|
|
GS169391: MP:0002066 abnormal motor capabilities/coordination/movement
|
|
GS176588: HP:0001272 Cerebellar atrophy
|
|
GS175528: HP:0000007 Autosomal recessive inheritance
|
|
GS176914: HP:0002171 Gliosis
|
|
GS136126: lipoprotein QTL 3 (Lipq3, Published QTL Chr 15)
|
|
GS182699: GO:0051174 regulation of phosphorus metabolic process
|
|
GS177031: HP:0011442 Abnormality of central motor function
|
|
GS185492: GO:0050789 regulation of biological process
|
|
GS188699: GO:0003013 circulatory system process
|
|
GS173187: HP:0007772 Impaired smooth pursuit
|
|
GS181473: GO:0005488 binding
|
|
GS175526: HP:0000005 Mode of inheritance
|
|
GS167714: MP:0002414 abnormal myeloblast morphology/development
|
|
GS174836: HP:0001098 Abnormality of the fundus
|
|
GS180036: GO:0032501 multicellular organismal process
|
|
GS183148: GO:0007613 memory
|
|
GS188413: GO:0045834 positive regulation of lipid metabolic process
|
|
GS192512: GO:0003824 catalytic activity
|
|
GS206869: GO:0006655 phosphatidylglycerol biosynthetic process
|
|
GS173246: HP:0001332 Dystonia
|
|
GS207616: GO:0016020 membrane
|
|
GS213077: Genes with suggestive difference in (PWD) vs (PB6F1 + B6PF1 + B6) comparison
|
|
GS171647: HP:0011844 Abnormal appendicular skeleton morphology
|
|
GS175979: HP:0009115 Aplasia/Hypoplasia involving the skeleton
|
|
GS185720: GO:0015711 organic anion transport
|
|
GS83996: cocaine seizure 3 (Cosz3, Published QTL, Chr 15)
|
|
GS185880: GO:0035637 multicellular organismal signaling
|
|
GS123058: KT 5720 interacting genes (MeSH:C057416) in CTD
|
|
GS176170: HP:0001252 Muscular hypotonia
|
|
GS167326: MP:0002145 abnormal T cell differentiation
|
|
GS135425: bile mucin accumulation (Bmca, Published QTL Chr 15)
|
|
GS163601: MP:0002089 abnormal postnatal growth/weight/body size
|
|
GS177094: GO:0006629 lipid metabolic process
|
|
GS190015: GO:0046883 regulation of hormone secretion
|
|
GS192440: GO:0002793 positive regulation of peptide secretion
|
|
GS197244: GO:0044237 cellular metabolic process
|
|
GS178333: GO:0007268 synaptic transmission
|
|
GS189479: GO:0046513 ceramide biosynthetic process
|
|
GS196055: GO:0008654 phospholipid biosynthetic process
|
|
GS179132: GO:0044255 cellular lipid metabolic process
|
|
GS176029: HP:0009116 Aplasia/Hypoplasia involving bones of the skull
|
|
GS185954: GO:0090087 regulation of peptide transport
|
|
GS186867: GO:0032309 icosanoid secretion
|
|
GS177409: GO:0005739 mitochondrion
|
|
GS188471: GO:2000191 regulation of fatty acid transport
|
|
GS163662: MP:0005277 abnormal brainstem morphology
|
|
GS169367: MP:0005405 axon degeneration
|
|
GS184884: GO:0010941 regulation of cell death
|
|
GS171721: HP:0003445 EMG: neuropathic changes
|
|
GS165527: MP:0005378 growth/size phenotype
|
|
GS186067: GO:0050877 neurological system process
|
|
GS175529: HP:0000001 All
|
|
GS174135: HP:0002015 Dysphagia
|
|
GS176803: HP:0001260 Dysarthria
|
|
GS185770: GO:0006644 phospholipid metabolic process
|
|
GS193018: GO:0003008 system process
|
|
GS190458: GO:0090276 regulation of peptide hormone secretion
|
|
GS182690: GO:0046890 regulation of lipid biosynthetic process
|
|
GS190471: GO:0005829 cytosol
|
|
GS135967: HDL QTL 4 (Hdlq4, Published QTL Chr 15)
|
|
GS201237: GO:0046486 glycerolipid metabolic process
|
|
GS169767: MP:0002396 abnormal hematopoietic system morphology/development
|
|
GS184447: GO:0044424 intracellular part
|
|
GS207862: GO:0009056 catabolic process
|
|
GS187067: GO:0046879 hormone secretion
|
|
GS193236: GO:0031326 regulation of cellular biosynthetic process
|
|
GS186864: GO:0032303 regulation of icosanoid secretion
|
|
GS188234: GO:0033043 regulation of organelle organization
|
|
GS178838: GO:0010562 positive regulation of phosphorus metabolic process
|
|
GS209863: GO:0050896 response to stimulus
|
|
GS169777: MP:0002398 abnormal bone marrow cell morphology/development
|
|
GS171307: HP:0003444 EMG: chronic denervation signs
|
|
GS178360: GO:0071841 cellular component organization or biogenesis at cellular level
|
|
GS177598: GO:0043412 macromolecule modification
|
|
GS183681: GO:0009743 response to carbohydrate stimulus
|
|
GS172944: HP:0100314 Cerebral inclusion bodies
|
|
GS186740: GO:0043229 intracellular organelle
|
|
GS115115: QTL for VEC in the LS x SS RI Strains
|
|
GS190087: GO:2000304 positive regulation of ceramide biosynthetic process
|
|
GS166712: MP:0002161 abnormal fertility/fecundity
|
|
GS175191: HP:0002060 Abnormality of the cerebrum
|
|
GS188957: GO:0033036 macromolecule localization
|
|
GS167567: MP:0008571 abnormal synaptic bouton morphology
|
|
GS193122: GO:0090153 regulation of sphingolipid biosynthetic process
|
|
GS122489: 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one interacting genes (MeSH:C068314) in CTD
|
|
GS166250: MP:0008247 abnormal mononuclear cell morphology
|
|
GS179671: GO:0030001 metal ion transport
|
|
GS179672: GO:0030003 cellular cation homeostasis
|
|
GS181450: GO:0031399 regulation of protein modification process
|
|
GS176568: HP:0000486 Strabismus
|
|
GS136053: IGF-1 serum levels 3 (Igf1sl3, Published QTL Chr 15)
|
|
GS187420: GO:0031644 regulation of neurological system process
|
|
GS176797: HP:0001268 Mental deterioration
|
|
GS182234: GO:0036211 protein modification process
|
|
GS193015: GO:0003001 generation of a signal involved in cell-cell signaling
|
|
GS184026: GO:0009914 hormone transport
|
|
GS208012: GO:0044464 cell part
|
|
GS210212: GO:0005575 cellular_component
|
|
GS122552: Thapsigargin interacting genes (MeSH:D019284) in CTD
|
|
GS186430: GO:0007243 intracellular protein kinase cascade
|
|
GS175407: HP:0002072 Chorea
|
|
GS177334: GO:0016192 vesicle-mediated transport
|
|
GS191400: GO:0010817 regulation of hormone levels
|
|
GS179160: GO:0042886 amide transport
|
|
GS192073: GO:1901576 organic substance biosynthetic process
|
|
GS185796: GO:0023061 signal release
|
|
GS188399: GO:0044238 primary metabolic process
|
|
GS194019: GO:0036152 phosphatidylethanolamine acyl-chain remodeling
|
|
GS192511: GO:0006816 calcium ion transport
|
|
GS188762: GO:0009889 regulation of biosynthetic process
|
|
GS180083: GO:0034220 ion transmembrane transport
|
|
GS190246: GO:0032409 regulation of transporter activity
|
|
GS865: Sey_Pax6_Age_Reduced_Linear_Incr
|
|
GS135225: absorbance of eye lens protein (Ablp, Published QTL Chr 15)
|
|
GS136521: phospholipid transfer protein activity QTL 4 (Pltpq4, Published QTL Chr 15)
|
|
GS136504: proteoglycan induced arthritis 9 (Pgia9, Published QTL Chr 15)
|
|
GS168422: MP:0000716 abnormal immune system cell morphology
|
|
GS166346: MP:0010047 axonal spheroids
|
|
GS186214: GO:0048518 positive regulation of biological process
|
|
GS187576: GO:0051128 regulation of cellular component organization
|
|
GS185788: GO:0045017 glycerolipid biosynthetic process
|
|
GS190459: GO:0090277 positive regulation of peptide hormone secretion
|
|
GS125445: Phenobarbital interacting genes (MeSH:D010634) in CTD
|
|
GS168295: MP:0003698 abnormal male reproductive system physiology
|
|
GS34261: Striatum Gene expression correlates of Suppression of activity in altered context in Males BXD
|
|
GS176101: HP:0000924 Abnormality of the skeletal system
|
|
GS179195: GO:0044070 regulation of anion transport
|
|
GS184220: GO:0071702 organic substance transport
|
|
GS183803: GO:0044267 cellular protein metabolic process
|
|
GS176801: HP:0001263 Global developmental delay
|
|
GS172195: HP:0000504 Abnormality of vision
|
|
GS189194: GO:0010959 regulation of metal ion transport
|
|
GS174500: HP:0000707 Abnormality of the nervous system
|
|
GS174922: HP:0000762 Decreased nerve conduction velocity
|
|
GS168149: MP:0005508 abnormal skeleton morphology
|
|
GS171998: HP:0001939 Abnormality of metabolism/homeostasis
|
|
GS203755: GO:0016265 death
|
|
GS187168: GO:0010648 negative regulation of cell communication
|
|
GS167020: MP:0003956 abnormal body size
|
|
GS164263: MP:0002083 premature death
|
|
GS169535: MP:0005397 hematopoietic system phenotype
|
|
GS165789: MP:0005369 muscle phenotype
|
|
GS186771: GO:0090200 positive regulation of release of cytochrome c from mitochondria
|
|
GS168530: MP:0008916 abnormal astrocyte physiology
|
|
GS182834: GO:0005623 cell
|
|
GS168021: MP:0000745 tremors
|
|
GS176167: HP:0001257 Spasticity
|
|
GS184852: GO:0072503 cellular divalent inorganic cation homeostasis
|
|
GS191151: GO:0010556 regulation of macromolecule biosynthetic process
|
|
GS136421: pain 1 (Pain1, Published QTL Chr 15)
|
|
GS115116: alcohol acceptance QTL 1 (Aaq1 , Published QTL, Chr 15)
|
|
GS173815: HP:0000736 Short attention span
|
|
GS189460: GO:0060255 regulation of macromolecule metabolic process
|
|
GS115112: Mean ethanol consumption 6 (Mec6, Published QTL, Chr 15)
|
|
GS169530: MP:0005390 skeleton phenotype
|
|
GS173617: HP:0011220 Prominent forehead
|
|
GS174914: HP:0003011 Abnormality of the musculature
|
|
GS180876: GO:0051240 positive regulation of multicellular organismal process
|
|
GS182474: GO:0043232 intracellular non-membrane-bounded organelle
|
|
GS185714: GO:0015718 monocarboxylic acid transport
|
|
GS199635: GO:0005622 intracellular
|
|
GS171217: HP:0003487 Babinski sign
|
|
GS169227: MP:0001405 impaired coordination
|
|
GS207365: GO:0005829 cytosol
|
|
GS186180: GO:0045937 positive regulation of phosphate metabolic process
|
|
GS196943: GO:0008152 metabolic process
|
|
GS180188: GO:0006869 lipid transport
|
|
GS213076: Genes with suggestive difference in (B6) vs (B6PF1 + PB6F1 + PWD) comparison
|
|
GS180305: GO:0016310 phosphorylation
|
|
GS187146: GO:0044700 single organism signaling
|
|
GS202625: GO:0045017 glycerolipid biosynthetic process
|
|
GS136882: T cell secretion of IL4 QTL 3 (Tsiq3, Published QTL Chr 15)
|
|
GS183433: GO:0030073 insulin secretion
|
|
GS136037: induction of brown adipocytes 8 (Iba8, Published QTL Chr 15)
|
|
GS192825: GO:0051966 regulation of synaptic transmission, glutamatergic
|
|
GS135663: cocaine seizure 3 (Cosz3, Published QTL Chr 15)
|
|
GS122142: Dietary Fats interacting genes (MeSH:D004041) in CTD
|
|
GS174075: HP:0009121 Abnormal axial skeleton morphology
|
|
GS196941: GO:0008150 biological_process
|
|
GS168838: MP:0003107 abnormal response to novelty
|
|
GS208043: GO:0016788 hydrolase activity, acting on ester bonds
|
|
GS199634: GO:0005623 cell
|
|
GS208298: GO:0005813 centrosome
|
|
GS164136: MP:0000001 mammalian phenotype
|
|
GS169386: MP:0002063 abnormal learning/memory/conditioning
|
|
GS188290: GO:0009966 regulation of signal transduction
|
|
GS166117: MP:0002108 abnormal muscle morphology
|
|
GS190778: GO:0051969 regulation of transmission of nerve impulse
|
|
GS175539: HP:0007256 Abnormality of pyramidal motor function
|
|
GS189990: GO:0006655 phosphatidylglycerol biosynthetic process
|
|
GS190901: GO:0043008 ATP-dependent protein binding
|
|
GS201256: GO:0044422 organelle part
|
|
GS84290: METH responses for home cage activity (Published QTL, Chr 15)
|
|
GS178953: GO:0032268 regulation of cellular protein metabolic process
|
|
GS172192: HP:0002185 Neurofibrillary tangles
|
|
GS182688: GO:0009746 response to hexose stimulus
|
|
GS175814: HP:0011024 Abnormality of the gastrointestinal tract
|
|
GS163026: MP:0000221 decreased leukocyte cell number
|
|
GS201431: GO:0005515 protein binding
|
|
GS184503: GO:0006874 cellular calcium ion homeostasis
|
|
GS188663: GO:0043269 regulation of ion transport
|
|
GS176613: HP:0000271 Abnormality of the face
|
|
GS136908: vertebral morphology and mechanical traits 13 (Vmmt13, Published QTL Chr 15)
|
|
GS165615: MP:0002123 abnormal hematopoiesis
|
|
GS187591: GO:0046887 positive regulation of hormone secretion
|
|
GS206284: GO:0035965 cardiolipin acyl-chain remodeling
|
|
GS184506: GO:0006873 cellular ion homeostasis
|
|
GS173147: HP:0011283 Abnormality of the metencephalon
|
|
GS183091: GO:0043270 positive regulation of ion transport
|
|
GS126276: pirinixic acid interacting genes (MeSH:C006253) in CTD
|
|
GS187160: GO:0044707 single-multicellular organism process
|
|
GS174305: HP:0000712 Emotional lability
|
|
GS193040: GO:0015909 long-chain fatty acid transport
|
|
GS168921: MP:0002675 asthenozoospermia
|
|
GS190125: GO:0042593 glucose homeostasis
|
|
GS190773: GO:0051967 negative regulation of synaptic transmission, glutamatergic
|
|
GS169185: MP:0000755 hindlimb paralysis
|
|
GS170825: HP:0002167 Neurological speech impairment
|
|
GS191954: GO:0005856 cytoskeleton
|
|
GS179592: GO:0006820 anion transport
|
|
GS174579: HP:0002031 Abnormality of the esophagus
|
|
GS136544: periosteal circumference 3 (Pstc3, Published QTL Chr 15)
|
|
GS184323: GO:0010647 positive regulation of cell communication
|
|
GS115118: A QTL region for alcohol preference
|
|
GS168551: MP:0002429 abnormal blood cell morphology/development
|
|
GS175117: HP:0001883 Talipes
|
|
GS181783: GO:0010604 positive regulation of macromolecule metabolic process
|
|
GS192898: GO:0042312 regulation of vasodilation
|
|
GS193059: GO:0044446 intracellular organelle part
|
|
GS176172: HP:0001251 Ataxia
|
|
GS135658: cocaine related behavior 14 (Cocrb14, Published QTL Chr 15)
|
|
GS187771: GO:1901566 organonitrogen compound biosynthetic process
|
|
GS186862: GO:0032305 positive regulation of icosanoid secretion
|
|
GS171274: HP:0100543 Cognitive impairment
|
|
GS209623: GO:0032049 cardiolipin biosynthetic process
|
|
GS169827: MP:0005387 immune system phenotype
|
|
GS183432: GO:0030072 peptide hormone secretion
|
|
GS175124: HP:0001884 Talipes calcaneovalgus
|
|
GS166641: MP:0010053 decreased grip strength
|
|
GS192437: GO:0002790 peptide secretion
|
|
GS136299: mean platelet volume locus 1 (Mpvq1, Published QTL Chr 15)
|
|
GS125062: palm oil interacting genes (MeSH:C041786) in CTD
|
|
GS199272: GO:0043232 intracellular non-membrane-bounded organelle
|
|
GS186899: GO:0016265 death
|
|
GS179001: GO:0001678 cellular glucose homeostasis
|
|
GS136723: susceptibility to lung cancer 26 (Sluc26, Published QTL Chr 15)
|
|
GS171848: HP:0000598 Abnormality of the ear
|
|
GS188556: GO:0042325 regulation of phosphorylation
|
|
GS163297: MP:0000217 abnormal leukocyte cell number
|
|
GS172516: HP:0001347 Hyperreflexia
|
|
GS33970: Striatum Gene expression correlates of Morphine distance (cm) travelled minutes 15-30 in Females & Males BXD
|
|
GS205047: GO:0006807 nitrogen compound metabolic process
|
|
GS165260: MP:0001392 abnormal locomotor behavior
|
|
GS170884: HP:0006919 Abnormal aggressive, impulsive or violent behavior
|
|
GS184629: GO:0005515 protein binding
|
|
GS190178: GO:0051050 positive regulation of transport
|
|
GS178099: GO:0090199 regulation of release of cytochrome c from mitochondria
|
|
GS187494: GO:0035774 positive regulation of insulin secretion involved in cellular response to glucose stimulus
|
|
GS193041: GO:0015908 fatty acid transport
|
|
GS169590: MP:0001415 increased exploration in new environment
|
|
GS171621: HP:0100851 Abnormal emotion/affect behavior
|
|
GS179211: GO:0007154 cell communication
|
|
GS192265: GO:0007165 signal transduction
|
|
GS168739: MP:0009417 skeletal muscle atrophy
|
|
GS180152: GO:0065007 biological regulation
|
|
GS192681: GO:0032049 cardiolipin biosynthetic process
|
|
GS163024: MP:0004819 decreased skeletal muscle mass
|
|
GS187497: GO:0035773 insulin secretion involved in cellular response to glucose stimulus
|
|
GS171661: HP:0000617 Abnormality of ocular smooth pursuit
|
|
GS175179: HP:0001310 Dysmetria
|
|
GS182312: GO:0044087 regulation of cellular component biogenesis
|
|
GS174462: HP:0002648 Abnormality of calvarial morphology
|
|
GS166743: MP:0002229 neurodegeneration
|
|
GS188558: GO:0042327 positive regulation of phosphorylation
|
|
GS165397: MP:0001265 decreased body size
|
|
GS170601: MP:0005621 abnormal cell physiology
|
|
GS135729: darker modification of yellow agouti QTL 3 (Dmyaq3, Published QTL Chr 15)
|
|
GS190678: GO:0007270 neuron-neuron synaptic transmission
|
|
GS169095: MP:0004924 abnormal behavior
|
|
GS188977: GO:0055074 calcium ion homeostasis
|
|
GS186700: GO:0090037 positive regulation of protein kinase C signaling cascade
|
|
GS84286: alcohol consumption (Published QTL, Chr 15)
|
|
GS172030: HP:0000365 Hearing impairment
|
|
GS135901: granulosa cell tumorigenesis 3 (Gct3, Published QTL Chr 15)
|
|
GS189326: GO:0048583 regulation of response to stimulus
|
|
GS135923: habituation QTL (Hbtq, Published QTL Chr 15)
|
|
GS173901: HP:0002007 Frontal bossing
|
|
GS189482: GO:0023056 positive regulation of signaling
|
|
GS187421: GO:0031645 negative regulation of neurological system process
|
|
GS208126: GO:0009605 response to external stimulus
|
|
GS192076: GO:1901571 fatty acid derivative transport
|
|
GS84284: alcohol acceptance (Published QTL, Chr 15)
|
|
GS169173: MP:0006387 abnormal T cell number
|
|
GS203594: GO:0043226 organelle
|
|
GS178807: GO:0032368 regulation of lipid transport
|
|
GS135692: directional asymmetry QTL 14 (Daq14, Published QTL Chr 15)
|
|
GS203381: GO:0009308 amine metabolic process
|
|
GS87011: Table S2: List of Cocaine-Treated HDAC5 KO vs. Cocaine-Treated WT Significantly Regulated Genes. [DRG]
provisional
|
|
GS210002: GO:0044444 cytoplasmic part
|
|
GS135992: hepatic fibrogenesis 1 (Hfib1, Published QTL Chr 15)
|
|
GS171168: HP:0000234 Abnormality of the head
|
|
GS179822: GO:0006468 protein phosphorylation
|
|
GS164022: MP:0008246 abnormal leukocyte morphology
|
|
GS191775: GO:0001836 release of cytochrome c from mitochondria
|
|
GS209009: GO:1901576 organic substance biosynthetic process
|
|
GS179441: GO:0009749 response to glucose stimulus
|
|
GS175197: HP:0002066 Gait ataxia
|
|
GS190949: GO:0009058 biosynthetic process
|
|
GS182705: GO:0051173 positive regulation of nitrogen compound metabolic process
|
|
GS185958: GO:0051046 regulation of secretion
|
|
GS165640: MP:0002269 muscular atrophy
|
|
GS167622: MP:0002152 abnormal brain morphology
|
|
GS194309: GO:0016042 lipid catabolic process
|
|
GS186255: GO:0033500 carbohydrate homeostasis
|
|
GS172372: HP:0000648 Optic atrophy
|
|
GS175668: HP:0007369 Atrophy/Degeneration affecting the cerebrum
|
|
GS168958: MP:0003492 abnormal involuntary movement
|
|
GS181102: GO:0043228 non-membrane-bounded organelle
|
|
GS165604: MP:0008503 abnormal spinal cord grey matter morphology
|
|
GS201060: GO:0042330 taxis
|
|
GS136012: heart rate quantitative locus 2 (Hrq2, Published QTL Chr 15)
|
|
GS185008: GO:0097190 apoptotic signaling pathway
|
|
GS136478: periosteal circumference 3 (Pcir3, Published QTL Chr 15)
|
|
GS210000: GO:0044446 intracellular organelle part
|
|
GS174131: HP:0002011 Abnormality of the central nervous system
|
|
GS169658: MP:0002572 abnormal emotion/affect behavior
|
|
GS194087: GO:0003674 molecular_function
|
|
GS171424: HP:0002814 Abnormality of the lower limb
|
|
GS191268: GO:0010033 response to organic substance
|
|
GS135437: bone mineral density 37 (Bmd37, Published QTL Chr 15)
|
|
GS184461: GO:0009891 positive regulation of biosynthetic process
|
|
GS175304: HP:0000290 Abnormality of the forehead
|
|
GS33975: Striatum Gene expression correlates of Morphine distance (cm) travelled minutes 30-45 in Females & Males BXD
|
|
GS174368: HP:0002080 Intention tremor
|
|
GS177356: GO:0003674 molecular_function
|
|
GS163227: MP:0003313 abnormal locomotor activation
|
|
GS203590: GO:0043229 intracellular organelle
|
|
GS187106: GO:0010822 positive regulation of mitochondrion organization
|
|
GS177717: GO:0051239 regulation of multicellular organismal process
|
|
GS176245: HP:0011443 Abnormality of coordination
|
|
GS176610: HP:0003593 Infantile onset
|
|
GS189823: GO:0071326 cellular response to monosaccharide stimulus
|
|
GS193285: GO:0004623 phospholipase A2 activity
|
|
GS170131: MP:0008415 abnormal neurite morphology
|
|
GS189559: GO:0001932 regulation of protein phosphorylation
|
|
GS195897: GO:0044255 cellular lipid metabolic process
|
|
GS83984: cocaine related behavior 15 (Cocrb15, Published QTL, Chr 15)
|
|
GS182061: GO:0006672 ceramide metabolic process
|
|
GS179285: GO:0008654 phospholipid biosynthetic process
|
|
GS180166: GO:0008152 metabolic process
|
|
GS176806: HP:0003812 Phenotypic variability
|
|
GS171832: HP:0000118 Phenotypic abnormality
|
|
GS188470: GO:2000193 positive regulation of fatty acid transport
|
|
GS173065: HP:0003679 Pace of progression
|
|
GS136245: methamphetamine response QTL 5 (Marq5, Published QTL Chr 15)
|
|
GS33985: Striatum Gene expression correlates of Morphine distance (cm) travelled minutes 60-75 in Females & Males BXD
|
|
GS183321: GO:0051130 positive regulation of cellular component organization
|
|
GS170362: MP:0000717 abnormal lymphocyte cell number
|
|
GS183410: GO:0015849 organic acid transport
|
|
GS191031: GO:0090238 positive regulation of arachidonic acid secretion
|
|
GS171100: HP:0000759 Abnormality of the peripheral nervous system
|
|
GS204384: GO:0006576 cellular biogenic amine metabolic process
|
|
GS174076: HP:0009122 Aplasia/Hypoplasia affecting bones of the axial skeleton
|
|
GS164724: MP:0001516 abnormal motor coordination/ balance
|
|
GS192509: GO:0006810 transport
|
|
GS187193: GO:0044057 regulation of system process
|
|
GS210230: GO:0004623 phospholipase A2 activity
|
|
GS84285: cocaine related behavior (Published QTL, Chr 15)
|
|
GS184182: GO:0032270 positive regulation of cellular protein metabolic process
|
|
GS169179: MP:0000753 paralysis
|
|
GS188033: GO:0010638 positive regulation of organelle organization
|
|
GS172989: HP:0001324 Muscle weakness
|
|
GS198640: GO:0046470 phosphatidylcholine metabolic process
|
|
GS174505: HP:0000708 Behavioural/Psychiatric Abnormality
|
|
GS179556: GO:0060627 regulation of vesicle-mediated transport
|
|
GS36493: Cerebellum Gene expression correlates of Morphine - Salivation in Males BXD
|
|
GS193812: GO:0006629 lipid metabolic process
|
|
GS183366: GO:0008637 apoptotic mitochondrial changes
|
|
GS168956: MP:0003491 abnormal voluntary movement
|
|
GS174508: HP:0100710 Impulsivity
|
|
GS191560: GO:0032370 positive regulation of lipid transport
|
|
GS187751: GO:0019222 regulation of metabolic process
|
|
GS115117: Free-choice ethanol consumption
|
|
GS168291: MP:0003690 abnormal glial cell physiology
|
|
GS176808: HP:0002067 Bradykinesia
|
|
GS169663: MP:0004703 abnormal vertebral column morphology
|
|
GS173787: HP:0002813 Abnormality of limb bone morphology
|
|
GS182981: GO:0043067 regulation of programmed cell death
|
|
GS185961: GO:0051049 regulation of transport
|
|
GS136551: proteinuria 4 (Ptnu4, Published QTL Chr 15)
|
|
GS165462: MP:0001524 impaired limb coordination
|
|
GS193237: GO:0031325 positive regulation of cellular metabolic process
|
|
GS176171: HP:0001250 Seizures
|
|
GS185708: GO:0014848 urinary tract smooth muscle contraction
|
|
GS195214: GO:0009987 cellular process
|
|
GS184452: GO:0044422 organelle part
|
|
GS182183: GO:0010876 lipid localization
|
|
GS184551: GO:0007005 mitochondrion organization
|
|
GS193773: GO:0070528 protein kinase C signaling cascade
|
|
GS165525: MP:0010768 mortality/aging
|
|
GS175673: HP:0100022 Abnormality of movement
|
|
GS193639: GO:0051641 cellular localization
|
|
GS135523: body weight QTL 12 (Bwtq12, Published QTL Chr 15)
|
|
GS180155: GO:0065009 regulation of molecular function
|
|
GS198636: GO:0046474 glycerophospholipid biosynthetic process
|
|
GS182391: GO:2001257 regulation of cation channel activity
|
|
GS165388: MP:0001263 weight loss
|
|
GS189535: GO:0010740 positive regulation of intracellular protein kinase cascade
|
|
GS192043: GO:0050482 arachidonic acid secretion
|
|
GS171148: HP:0011218 Abnormal shape of the frontal region
|
|
GS187166: GO:0044708 single-organism behavior
|
|
GS125409: Triiodothyronine interacting genes (MeSH:D014284) in CTD
|
|
GS169225: MP:0000358 abnormal cell morphology
|
|
GS168174: MP:0001919 abnormal reproductive system physiology
|
|
GS207923: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS135836: fluctuating asymmetry QTL 9 (Faq9, Published QTL Chr 15)
|
|
GS191135: GO:0016788 hydrolase activity, acting on ester bonds
|
|
GS175360: HP:0002529 Neuronal loss in central nervous system
|
|
GS192296: GO:0006796 phosphate-containing compound metabolic process
|
|
GS198263: GO:0005488 binding
|
|
GS181711: GO:0050805 negative regulation of synaptic transmission
|
|
GS189454: GO:0034762 regulation of transmembrane transport
|
|
GS180319: GO:0046942 carboxylic acid transport
|
|
GS86932: Table S3: CORTEX 17K MICROARRAY [DRG]
|
|
GS170152: MP:0001077 abnormal spinal nerve morphology
|
|
GS175169: HP:0001317 Abnormality of the cerebellum
|
|
GS192918: GO:0050896 response to stimulus
|
|
GS172373: HP:0000649 Abnormality of vision evoked potentials
|
|
GS195151: GO:0019637 organophosphate metabolic process
|
|
GS125669: Phenylephrine interacting genes (MeSH:D010656) in CTD
|
|
GS165524: MP:0010769 abnormal survival
|
|
GS83983: cocaine related behavior 14 (Cocrb14, Published QTL, Chr 15)
|
|
GS208037: GO:0016787 hydrolase activity
|
|
GS209235: GO:0006793 phosphorus metabolic process
|
|
GS136488: predicted fat percentage 4 (Pfat4, Published QTL Chr 15)
|
|
GS177508: GO:0046467 membrane lipid biosynthetic process
|
|
GS189840: GO:0035150 regulation of tube size
|
|
GS167999: MP:0002408 abnormal double-positive T cell morphology
|
|
GS185637: GO:0070887 cellular response to chemical stimulus
|
|
GS135806: emotionality 2 (Emo2, Published QTL Chr 15)
|
|
GS172100: HP:0000587 Abnormality of the optic nerve
|
|
GS194905: GO:0008219 cell death
|
|
GS208302: GO:0005815 microtubule organizing center
|
|
GS210357: GO:0044249 cellular biosynthetic process
|
|
GS172362: HP:0004325 Decreased body weight
|
|
GS180452: GO:0044237 cellular metabolic process
|
|
GS188581: GO:1900117 regulation of execution phase of apoptosis
|
|
GS195332: GO:0047499 calcium-independent phospholipase A2 activity
|
|
GS193614: GO:0071310 cellular response to organic substance
|
|
GS172353: HP:0004329 Abnormality of the posterior segment of the eye
|
|
GS187593: GO:0046889 positive regulation of lipid biosynthetic process
|
|
GS136683: skull morphology 22 (Skull22, Published QTL Chr 15)
|
|
GS183151: GO:0007611 learning or memory
|
|
GS167589: MP:0005016 decreased lymphocyte cell number
|
|
GS190124: GO:0042592 homeostatic process
|
|
GS188751: GO:0044430 cytoskeletal part
|
|
GS174453: HP:0001438 Abnormality of the abdomen
|
|
GS180164: GO:0008150 biological_process
|
|
GS181808: GO:0032890 regulation of organic acid transport
|
|
GS186658: GO:0030148 sphingolipid biosynthetic process
|
|
GS177667: GO:0006665 sphingolipid metabolic process
|
|
GS176333: HP:0007319 Morphological abnormality of the central nervous system
|
|
GS177531: GO:0043170 macromolecule metabolic process
|
|
GS194460: GO:0090407 organophosphate biosynthetic process
|
|
GS184641: GO:0032024 positive regulation of insulin secretion
|
|
GS205255: GO:0044238 primary metabolic process
|
|
GS186108: GO:0006936 muscle contraction
|
|
GS124286: Benzene interacting genes (MeSH:D001554) in CTD
|
|
GS180482: GO:0033554 cellular response to stress
|
|
GS194017: GO:0036151 phosphatidylcholine acyl-chain remodeling
|
|
GS181483: GO:0035556 intracellular signal transduction
|
|
GS187769: GO:1901564 organonitrogen compound metabolic process
|
|
GS14890: Downregulated genes in five combined brain regions, Amyg, HP, NA, PFC and VTA, in C57BL/6J mice
|
|
GS175404: HP:0002075 Dysdiadochokinesis
|
|
GS190448: GO:0045909 positive regulation of vasodilation
|
|
GS185773: GO:0006643 membrane lipid metabolic process
|
|
GS209232: GO:0006796 phosphate-containing compound metabolic process
|
|
GS175408: HP:0002071 Abnormality of extrapyramidal motor function
|
|
GS185997: GO:0032412 regulation of ion transmembrane transporter activity
|
|
GS34265: Cerebellum Gene expression correlates of Suppression of activity in altered context in Males BXD
|
|
GS177721: GO:0051234 establishment of localization
|
|
GS163560: MP:0008037 abnormal T cell morphology
|
|
GS184502: GO:0006875 cellular metal ion homeostasis
|
|
GS165465: MP:0003633 abnormal nervous system physiology
|
|
GS184433: GO:0046486 glycerolipid metabolic process
|
|
GS190329: GO:2001233 regulation of apoptotic signaling pathway
|
|
GS190954: GO:0009056 catabolic process
|
|
GS209455: GO:0003824 catalytic activity
|
|
GS122305: resveratrol interacting genes (MeSH:C059514) in CTD
|
|
GS135706: diabetes susceptibility QTL 2 (Dbsq2, Published QTL Chr 15)
|
|
GS184218: GO:0071704 organic substance metabolic process
|
|
GS181708: GO:0050801 ion homeostasis
|
|
GS209624: GO:0032048 cardiolipin metabolic process
|
|
GS193563: GO:0006950 response to stress
|
|
GS170930: HP:0001284 Areflexia
|
|
GS190088: GO:2000303 regulation of ceramide biosynthetic process
|
|
GS126769: Calcium interacting genes (MeSH:D002118) in CTD
|
|
GS183848: GO:0044260 cellular macromolecule metabolic process
|
|
GS185830: GO:0007204 elevation of cytosolic calcium ion concentration
|
|
GS186110: GO:0006939 smooth muscle contraction
|
|
GS180878: GO:0051246 regulation of protein metabolic process
|
|
GS167918: MP:0000955 abnormal spinal cord morphology
|
|
GS177722: GO:0090407 organophosphate biosynthetic process
|
|
GS177785: GO:0090237 regulation of arachidonic acid secretion
|
|
GS164220: MP:0002882 abnormal neuron morphology
|
|
GS167566: MP:0005018 decreased T cell number
|
|
GS190397: GO:0032879 regulation of localization
|
|
GS170917: HP:0100852 Abnormal fear/anxiety-related behavior
|
|
GS185593: GO:0071333 cellular response to glucose stimulus
|
|
GS187749: GO:0019220 regulation of phosphate metabolic process
|
|
GS172666: HP:0011804 Abnormality of muscle physiology
|
|
GS35967: Striatum Gene expression correlates of Handling induced convulsion score in Males BXD
|
|
GS175107: HP:0003808 Abnormal muscle tone
|
|
GS175900: HP:0009118 Aplasia/Hypoplasia of the mandible
|
|
GS190950: GO:0009059 macromolecule biosynthetic process
|
|
GS178260: GO:0061178 regulation of insulin secretion involved in cellular response to glucose stimulus
|
|
GS178461: GO:0009987 cellular process
|
|
GS193061: GO:0044444 cytoplasmic part
|
|
GS192624: GO:0043231 intracellular membrane-bounded organelle
|
|
GS186743: GO:0043227 membrane-bounded organelle
|
|
GS189995: GO:0006650 glycerophospholipid metabolic process
|
|
GS165253: MP:0001399 hyperactivity
|
|
GS187033: GO:0006887 exocytosis
|
|
GS179830: GO:0006464 cellular protein modification process
|
|
GS192667: GO:0055080 cation homeostasis
|
|
GS181892: GO:0048523 negative regulation of cellular process
|
|
GS193268: GO:0005575 cellular_component
|
|
GS173786: HP:0003457 EMG abnormality
|
|
GS188190: GO:0006807 nitrogen compound metabolic process
|
|
GS184217: GO:0071705 nitrogen compound transport
|
|
GS193151: GO:0032940 secretion by cell
|
|
GS192920: GO:0050890 cognition
|
|
GS188291: GO:0009967 positive regulation of signal transduction
|
|
GS172189: HP:0002180 Neurodegeneration
|
|
GS187683: GO:0046717 acid secretion
|
|
GS176817: HP:0011446 Abnormality of higher mental function
|
|
GS189718: GO:0034284 response to monosaccharide stimulus
|
|
GS181059: GO:1901339 regulation of store-operated calcium channel activity
|
|
GS172170: HP:0003196 Short nose
|
|
GS205610: GO:0044430 cytoskeletal part
|
|
GS172032: HP:0000366 Abnormality of the nose
|
|
GS86494: Table S1: Hippocampus 17 K microarray data. [DRG]
|
|
GS172801: HP:0000752 Hyperactivity
|
|
GS175193: HP:0002062 Abnormality of the pyramidal tracts
|
|
GS207857: GO:0009058 biosynthetic process
|
|
GS182313: GO:0044085 cellular component biogenesis
|
|
GS192986: GO:0006996 organelle organization
|
|
GS169927: MP:0004174 abnormal spine curvature
|
|
GS165466: MP:0003632 abnormal nervous system morphology
|
|
GS163956: MP:0011180 abnormal hematopoietic cell number
|
|
GS169835: MP:0005389 reproductive system phenotype
|
|
GS186534: GO:0051970 negative regulation of transmission of nerve impulse
|
|
GS192682: GO:0032048 cardiolipin metabolic process
|
|
GS201023: GO:0071704 organic substance metabolic process
|
|
GS189483: GO:0023057 negative regulation of signaling
|
|
GS84287: cocaine induced activation (Published QTL, Chr 15)
|
|
GS171893: HP:0011458 Abdominal symptom
|
|
GS184566: GO:0019538 protein metabolic process
|
|
GS193286: GO:0004620 phospholipase activity
|
|
GS169228: MP:0001406 abnormal gait
|
|
GS170964: HP:0000152 Abnormality of head and neck
|
|
GS181426: GO:0022898 regulation of transmembrane transporter activity
|
|
GS164030: MP:0004817 abnormal skeletal muscle mass
|
|
GS164681: MP:0004262 abnormal physical strength
|
|
GS191106: GO:0044464 cell part
|
|
GS191379: GO:0005815 microtubule organizing center
|
|
GS179517: GO:0012501 programmed cell death
|
|
GS177570: GO:0016043 cellular component organization
|
|
GS208893: GO:0005856 cytoskeleton
|
|
GS172031: HP:0000364 Hearing abnormality
|
|
GS192669: GO:0055082 cellular chemical homeostasis
|
|
GS167991: MP:0002401 abnormal lymphopoiesis
|
|
GS174760: HP:0002376 Developmental regression
|
|
GS125390: Aspirin interacting genes (MeSH:D001241) in CTD
|
|
GS181810: GO:0032892 positive regulation of organic acid transport
|
|
GS184849: GO:0072507 divalent inorganic cation homeostasis
|
|
GS123990: perfluorooctanoic acid interacting genes (MeSH:C023036) in CTD
|
|
GS171453: HP:0003674 Onset
|
|
GS171806: HP:0005656 Positional foot deformities
|
|
GS163226: MP:0003312 abnormal locomotor coordination
|
|
GS164133: MP:0005076 abnormal cell differentiation
|
|
GS169176: MP:0000759 abnormal skeletal muscle morphology
|
|
GS167810: MP:0000160 kyphosis
|
|
GS174292: HP:0011968 Feeding difficulties
|
|
GS187487: GO:1901019 regulation of calcium ion transmembrane transporter activity
|
|
GS200827: GO:0006066 alcohol metabolic process
|
|
GS171277: HP:0100547 Abnormality of the forebrain
|
|
GS192074: GO:1901575 organic substance catabolic process
|
|
GS178155: GO:0008219 cell death
|
|
GS198072: GO:0042439 ethanolamine-containing compound metabolic process
|
|
GS135423: bleomycin-induced pulmonary fibrosis 4 (Blmpf4, Published QTL Chr 15)
|
|
GS173146: HP:0011282 Abnormality of the hindbrain
|
|
GS189374: GO:0042981 regulation of apoptotic process
|
|
GS14889: Differentially expressed genes modulated by nicotine in five combined brain regions (Amyg, HP, NA, PFC and VTA) for C57BL/6J mice
|
|
GS185585: GO:0044710 single-organism metabolic process
|
|
GS193123: GO:0090154 positive regulation of sphingolipid biosynthetic process
|
|
GS187708: GO:0009893 positive regulation of metabolic process
|
|
GS173137: HP:0011821 Abnormality of facial skeleton
|
|
GS181843: GO:0046474 glycerophospholipid biosynthetic process
|
|
GS193632: GO:0051649 establishment of localization in cell
|
|
GS172134: HP:0000639 Nystagmus
|
|
GS171999: HP:0001760 Abnormality of the foot
|
|
GS196667: GO:0008610 lipid biosynthetic process
|
|
GS179078: GO:0051480 cytosolic calcium ion homeostasis
|
|
GS202602: GO:0006644 phospholipid metabolic process
|
|
GS171944: HP:0003324 Generalized muscle weakness
|
|
GS189165: GO:0072511 divalent inorganic cation transport
|
|
GS181853: GO:0045921 positive regulation of exocytosis
|
|
GS182923: GO:0015833 peptide transport
|
|
GS135876: femur geometry 13 (Fmgty13, Published QTL Chr 15)
|
|
GS165395: MP:0003225 axonal dystrophy
|
|
GS135977: wound healing/regeneration 4 (Heal4, Published QTL Chr 15)
|
|
GS191593: GO:0055065 metal ion homeostasis
|
|
GS197967: GO:0052689 carboxylic ester hydrolase activity
|
|
GS172360: HP:0004323 Abnormality of body weight
|
|
GS180156: GO:0065008 regulation of biological quality
|
|
GS197892: GO:0043228 non-membrane-bounded organelle
|
|
GS189484: GO:0023052 signaling
|
|
GS135714: diabesity 4 (Dbsty4, Published QTL Chr 15)
|
|
GS181712: GO:0050804 regulation of synaptic transmission
|